Data Show Substantial Taste Changes in Head and Neck Cancer Following RT

Commentary
Video

Study results appear to affirm anecdotal information from patients with head and neck cancer related to taste changes during and after radiotherapy.

Noah S. Kalman, MD, MBA, spoke with CancerNetwork® about findings from a prospective study presented at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting showing significant changes in the ability to perceive taste among patients with head and neck cancer who undergo radiotherapy.

According to Kalman, a radiation oncologist specializing in the treatment of gynecologic, head and neck, thoracic and pediatric cancers, melanoma and non-melanoma skin cancers, and sarcoma at Miami Cancer Institute of Baptist Health Medical Group, data collected via an objective Waterless Empirical Taste Test were consistent with anecdotal information from patients who reported experiences with taste changes following radiotherapy. Overall, taste test scores among this patient population tended to decrease over the course of their treatment.

In total, the relative percentage change in taste at the end of treatment was –16.89%. Specifically, relative changes at the end of treatment based on specific tastes included –9.8% for sweet, –27.03% for sour, –30.36% for salty, –14.88% for bitter, and –65.93% for umami.

Analysis indicated that relative taste changes at the end of therapy strongly correlated with mean tongue doses (Pearson coefficient [r]: –0.6; P <.05). Investigators also noted a moderate association between relative taste changes at this period and oral cavity mean dose (r: –0.54; P <.05).

Transcript:

For our patients undergoing head and neck radiation, we see that their ability to discriminate taste, and so their overall score on these taste tests, go down. This is very much expected. We receive this information anecdotally from our patients, and this is also how we use our subjective grading, and so [the study results are] consistent with that. Over the first 2 to 4 weeks, the patients’ taste decreases substantially, and that continues through the end of treatment. Then as we get past treatment, we have a taste test at the 3-month mark; at that point, these patients are starting to experience recovery of their taste.

Reference

Yarlagadda S, Alzmanzar A, Rubens M, Kalman N. Taste changes in patients receiving head and neck radiation – initial analysis from a prospective study. Presented at: 2024 American Society for Radiation Oncology Annual Meeting; September 29-October 2, 2024; Washington, DC. Abstract 3762.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content